Observational studyMedicine2026
Assessment of angiopoietin-1, angiopoietin-2, Tie-2, EphrinB2, EphB4, and endocan serum level in patients with Behçet disease: A cross-sectional observational study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet disease (BD) is an inflammatory disorder with significant ocular involvement. Angiopoietins regulate vascular stability, while EphrinB2/EphB4 interactions are essential for retinal neovascularization and endothelial behavior. Endocan, a marker of endothelial activation, contributes to inflammatory processes by mediating leukocyte migration. This cross-sectional study investigates the role of angiopoietins, EphrinB2/EphB4 signaling, and endocan in the development of active uveitis in BD patients. We recruited 29 BD patients with active eye involvement (group 1), 31 BD patients without eye involvement (group 2), and 30 healthy controls (group 3). Serum tyrosine protein kinase receptor (Tie-2), angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), EphrinB2, EphB4, and endocan levels were determined by the enzyme-linked immunosorbent assay method. A statistically significant difference was found between the Ang-1, Ang-2, Tie-2, EphrinB2, EphB4, and endocan levels of the 3 different groups in the study (P < .05). Between the patients with panuveitis and patients with only posterior or anterior uveitis, serum Ang-1 (P < .001), Tie-2 (P < .001), EphrinB2 (P < .001), EphB4 (P = .001), and endocan (P = .002) levels had statistically significant differences. The highest and significant correlation was found between EphrinB2 and EphB4 (r = 0.931, P < .001). This was followed by a high level of significant correlation between Ang-1 and Ang-2 (r = -0.845, P < .001). In the group with active uveitis, EphB4 (r = -0.774), Ang-2 (r = -0.763), and Tie-2 (r = -0.701) were negatively and highly significantly correlated with best corrected visual acuity (P < .001). Ang-1, Ang-2, Tie-2, EphrinB2, EphB4, and endocan regulate vascular stability, retinal neovascularization, and inflammation, potentially contributing to BD-associated uveitis. These findings could have important implications for the diagnosis and management of ocular involvement of BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.